SPRO Latest Press Releases

-- October 26, 2026 --

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline Globe Newswire 8:00 AM

-- October 15, 2026 --

Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference Globe Newswire 4:05 PM

-- October 2, 2026 --

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- September 3, 2026 --

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- September 2, 2026 --

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference Globe Newswire 4:01 PM

-- August 12, 2026 --

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update Globe Newswire 4:01 PM

-- August 5, 2026 --

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- August 4, 2026 --

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 Globe Newswire 4:01 PM

-- July 27, 2026 --

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer Globe Newswire 8:00 AM

-- July 14, 2026 --

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties Globe Newswire 6:02 AM

Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody PRNewswire 6:00 AM

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody Globe Newswire 6:00 AM

-- July 8, 2026 --

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors Globe Newswire 2:00 AM

-- June 29, 2026 --

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer Globe Newswire 7:30 AM

-- June 17, 2026 --

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) Business Wire 4:21 PM

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) Globe Newswire 12:36 PM

Market Data Delayed 15 Minutes